4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole
C50H29N3O2S — CID 121425714
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole
4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole (PubChem CID 121425714) has the molecular formula C50H29N3O2S and a molecular weight of 735.87 g/mol. Its IUPAC name is 4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole.
Molecular Properties
| Compound Name | 4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole |
|---|---|
| PubChem CID | 121425714 |
| Molecular Formula | C50H29N3O2S |
| Molecular Weight | 735.87 g/mol |
| Exact Mass | 735.20 |
| IUPAC Name | 4,7-di(dibenzofuran-2-yl)-2-[4-(1-phenylbenzimidazol-2-yl)phenyl]-1,3-benzothiazole |
| SMILES | c1ccc(-n2c(-c3ccc(-c4nc5c(-c6ccc7oc8ccccc8c7c6)ccc(-c6ccc7oc8ccccc8c7c6)c5s4)cc3)nc3ccccc32)cc1 |
| InChI | InChI=1S/C50H29N3O2S/c1-2-10-34(11-3-1)53-42-15-7-6-14-41(42)51-49(53)30-18-20-31(21-19-30)50-52-47-35(32-22-26-45-39(28-32)37-12-4-8-16-43(37)54-45)24-25-36(48(47)56-50)33-23-27-46-40(29-33)38-13-5-9-17-44(38)55-46/h1-29H |
| InChIKey | BEBMYEAVHWHYSO-UHFFFAOYSA-N |
| XLogP | 14.10 |
| TPSA | 56.99 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 56 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 735.87 |
| LogP ≤ 5 | 14.10 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 121425714 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.